Reuben Gregg Brewer, The Motley Fool: "Prediction: This Is Where Pfizer Stock Will Be in 2030"
The author argues that Pfizer's high dividend yield reflects investor concerns over impending patent expirations for key drugs like Ibrance and Eliquis. While acknowledging pipeline risks, the commentary contends that Pfizer's acquisition strategy and recent GLP-1 pivot position it to replace lost revenue by 2030.